Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Serlopitant"'
Publikováno v:
Dermatology and Therapy, Vol 9, Iss 3, Pp 391-405 (2019)
Abstract The discovery of the first neurokinin 1 (NK-1) receptor antagonist was a turning point in the prevention of chemotherapy-induced nausea and vomiting. The NK-1 antagonists are a novel class of drugs that possess antidepressant, anxiolytic, an
Externí odkaz:
https://doaj.org/article/813fb2ed447b4df6a431d1ac6ff206c1
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Journal of the American Academy of Dermatology. 82:1314-1320
Background Pruritus, a common symptom of psoriasis, negatively affects quality of life; however, treatment of lesional skin does not consistently alleviate psoriatic itch. Objective To examine the effects of serlopitant, an oral, once-daily neurokini
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c404f43b580562cce9153630bb706b5c
https://doi.org/10.1016/j.jaad.2020.01.056
https://doi.org/10.1016/j.jaad.2020.01.056
Publikováno v:
Dermatology and Therapy
Dermatology and Therapy, Vol 9, Iss 3, Pp 391-405 (2019)
Dermatology and Therapy, Vol 9, Iss 3, Pp 391-405 (2019)
The discovery of the first neurokinin 1 (NK-1) receptor antagonist was a turning point in the prevention of chemotherapy-induced nausea and vomiting. The NK-1 antagonists are a novel class of drugs that possess antidepressant, anxiolytic, and antieme
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7feb023567fdbd345bf002ce059fd133
https://doi.org/10.1007/s13555-019-0305-2
https://doi.org/10.1007/s13555-019-0305-2
Autor:
Paul Kwon, Thomas A. Luger, Sonja Ständer, Martin Metz, Elke Weisshaar, Andrew J. Perlman, Joe Hirman
Publikováno v:
Journal of the American Academy of Dermatology. 80:1395-1402
Anecdotal evidence suggests that neurokinin 1 receptor antagonism reduces pruritus intensity in chronic pruritic conditions such as prurigo nodularis (PN).This study assessed safety and efficacy of the neurokinin 1 receptor antagonist serlopitant for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4081b8e432d58b3cf209257c3177045d
https://doi.org/10.1016/j.jaad.2019.01.052
https://doi.org/10.1016/j.jaad.2019.01.052
Publikováno v:
Dermatologic Therapy. 34
Accumulating evidence has showed the possibility of using NK1R antagonists for the treatment of chronic pruritus. However, the benefit and risk profile of NK1R antagonists-serlopitant and aprepitant for the treatment of pruritus remains unclear. To a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6155417e78297adff06ba96e5221da72
https://doi.org/10.1111/dth.14698
https://doi.org/10.1111/dth.14698
Publikováno v:
Expert opinion on investigational drugs. 28(8)
Introduction: Pruritus is a common symptom associated with several potential underlying causes, including both dermatologic and systemic diseases; it can also occur without an identifiable cause. Current treatment options are limited and most patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44810ab06e2d6e676d8f414d4fa3a698
https://pubmed.ncbi.nlm.nih.gov/31272246
https://pubmed.ncbi.nlm.nih.gov/31272246
Autor:
Sara Choi, Daniel Solis, I. Bailey-Healy, Albert S. Chiou, Kim Shu, Mark Joing, Jean Y. Tang, Shufeng Li, J. Nazaroff, M. Barriga, Paul Kwon, Yana Dutt-Singkh
Publikováno v:
Journal of the American Academy of Dermatology. 82(6)
Background Chronic pruritus causes major morbidity in epidermolysis bullosa (EB). The substance P-neurokinin 1 receptor (SP-NK1) pathway is a promising target for treating EB-related pruritus. Objective To evaluate the safety and efficacy of the oral
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d47cb27752e76dc62aa8ddd4c8cc777
https://pubmed.ncbi.nlm.nih.gov/31541747
https://pubmed.ncbi.nlm.nih.gov/31541747
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Manuel P. Pereira, Sonja Ständer
Publikováno v:
Expert opinion on investigational drugs. 27(12)
Chronic pruritus (CP) is a multidimensional condition severely affecting the quality of life of those affected. Although a multitude of topical and systemic agents are recommended for CP of different origins, the condition often remains refractory to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45de6b9a713da4a5c2507402be4d6cc3
https://pubmed.ncbi.nlm.nih.gov/30426802
https://pubmed.ncbi.nlm.nih.gov/30426802